Cancers, Vol. 14, Pages 4086: Adverse Renal Effects of Anticancer Immunotherapy: A Review
Chudek
Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated w...
Source: Cancers - August 23, 2022 Category: Cancer & Oncology Authors: Maciej Bor ówka Stanis ław Łącki-Zynzeling Micha ł Nicze Sylwia Kozak Jerzy Chudek Tags: Review Source Type: research
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Chronic inflammation is highly prevalent among patients receiving maintenance hemodialysis and is associated with morbidity and mortality. Inhibiting inflammation with anti-cytokine therapy has been proposed but not well studied in this population. Therefore, we conducted the ACTION trial, a pilot, multicenter, randomized, placebo-controlled trial of an IL-1 receptor antagonist, anakinra, to evaluate safety, tolerability, and feasibility, and explore efficacy. Eighty hemodialysis patients with plasma concentrations of high sensitivity C-reactive protein (hsCRP) 2 mg/L and above were randomized 1:1 to placebo or anakinra 10...
Source: Kidney International - July 18, 2022 Category: Urology & Nephrology Authors: Laura M. Dember, Adriana Hung, Rajnish Mehrotra, Jesse Y. Hsu, Dominic S. Raj, David M. Charytan, Finnian R. Mc Causland, Renu Regunathan-Shenk, J. Richard Landis, Paul L. Kimmel, Alan S. Kliger, Jonathan Himmelfarb, T. Alp Ikizler Tags: clinical trial Source Type: research
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Chronic inflammation is highly prevalent among patients receiving maintenance hemodialysis and is associated with morbidity and mortality. Inhibiting inflammation with anti-cytokine therapy has been proposed but not well studied in this population. Therefore, we conducted the ACTION trial, a pilot, multicenter, randomized, placebo-controlled trial of an IL-1 receptor antagonist, anakinra, to evaluate safety, tolerability, and feasibility, and explore efficacy. Eighty hemodialysis patients with plasma concentrations of high sensitivity C-reactive protein (hsCRP) 2 mg/L and above were randomized 1:1 to placebo or anakinra 10...
Source: Kidney International - July 18, 2022 Category: Urology & Nephrology Authors: Laura M. Dember, Adriana Hung, Rajnish Mehrotra, Jesse Y. Hsu, Dominic S. Raj, David M. Charytan, Finnian R. Mc Causland, Renu Regunathan-Shenk, J. Richard Landis, Paul L. Kimmel, Alan S. Kliger, Jonathan Himmelfarb, T. Alp Ikizler, Hemodialysis Novel The Tags: clinical trial Source Type: research
Biology of interleukin-37 and its role in autoimmune diseases (Review)
Exp Ther Med. 2022 Jun 7;24(2):495. doi: 10.3892/etm.2022.11422. eCollection 2022 Aug.ABSTRACTAutoimmune diseases (AIDs) are characterized by dysfunction and tissue destruction, and recent studies have shown that interleukin (IL)-37 expression is dysregulated in AIDs. Among cytokines of the IL-1 family, most are pro-inflammatory agents, and as an anti-inflammatory cytokine, IL-37 may have the potential to alleviate excessive inflammation and can be used as a ligand or transcription factor that is involved in regulating innate and adaptive immunity. IL-37 plays important roles in the development of AIDs. This review summari...
Source: Experimental and Therapeutic Medicine - July 15, 2022 Category: General Medicine Authors: Huiqiong Zeng Kaixia Zhou Zhizhong Ye Source Type: research
